KYVERNA THERAPEUTICS INC

Kyverna Therapeutics (KYTX) drops 3.3% after a 22% year‑to‑date decline. Learn key stats, peer comparison, and market insights for this biotech.

Kyverna Therapeutics (KYTX) slid 3.3% to $5.84, falling 22% month‑to‑date as investors weigh its oncology‑focused biotech pipeline and IPO prospects.

Kyverna Therapeutics stock rises 3.6% as Phase‑2 trial shows durable remission in stiff‑person syndrome, sparking investor interest.